Baseline data for patients with FSGS treated with adrenocorticotropic hormone
Patient | Age/(yr)/Sex | Race/Ethnicity | FSGS Morphology | Previous Immunosuppression | Steroid Response Category | Time from Diagnosis to Treatment (mo) | Serum Creatinine (mg/dl) | eGFR (ml/min per 1.73 m2) | Proteinuria (mg/g) |
---|---|---|---|---|---|---|---|---|---|
Columbia patients | |||||||||
1 | 42/Male | WNH | NOS | Steroids, MMF, tacrolimusa | SR | 2b | 2.7 | 28 | 7000 |
2 | 38/Female | BNH | NOS | Steroids, MMF, cyclosporine | SR | 56 | 2.3 | 31 | 5046 |
3 | 21/Female | WNH | Tip | Steroids, tacrolimus, cyclosporine | SD | 12 | 1.1 | 67 | 5200 |
4 | 40/Male | WNH | Tip | Steroids, tacrolimus, cyclosporine, MMF | SR | 96 | 1.2 | 71 | 2100 |
5 | 18/Male | BNH | Tip | Steroids, tacrolimus, MMF | SR | 13 | 2.6 | 42 | 11,200 |
6 | 46/Male | WNH | NOS | Steroids, cyclophosphamide, MMF, tacrolimus | SD | 30 | 3.2 | 23 | 16,800 |
7 | 64/Female | WH | Cellular | Steroids, MMF, tacrolimus, | SD | 61 | 1.6 | 35 | 10,300 |
8 | 60/Female | WNH | Cellular | Steroids, tacrolimus, MMF, cyclosporine | SR | 23 | 2.3 | 23 | 2300 |
9 | 66/Male | WNH | Tip | Steroids, cyclosporine, MMF | SR | 132 | 1.0 | 66 | 1600 |
10 | 36/Male | WNH | NOS | Steroids, cyclosporine | SR | 96 | 0.8 | 116 | 2200 |
11 | 30/Female | WNH | Tip | Steroids, MMF, cyclosporine, tacrolimus | SR | 13 | 3.4 | 17 | 8800 |
12 | 47/Female | BH | Tip | Steroids, tacrolimusa | SR | 4 | 3.6 | 17 | 15,200 |
Stanford patients | |||||||||
13 | 66/Male | WH | NOS | Steroids | SR | 14 | 2.2 | 30 | 2020 |
14 | 65/Male | WNH | Cellular | None | NA | 8 | 2.7 | 24 | 3170 |
15 | 64/Male | WNH | NOS | Steroids | SD | 22 | 1.04 | 76 | 7240 |
16 | 27/Male | WH | NOS | Steroids, cyclosporine | SR | 28 | 2.99 | 35 | 2200 |
17 | 58/Male | WNH | Tip | None | NA | 4 | 2.2 | 32 | 3550 |
18 | 29/Male | BNH | Collapsing | Steroids, MMF | SR | 6 | 3.3 | 28 | 23,800 |
19 | 28/Female | WH | Tip | Cyclosporine | NA | 19 | 0.6 | 124 | 4860 |
20 | 40/Male | WH | NOS | Steroids | SD | 29 | 1.1 | 84 | 2320 |
21 | 39/Female | WH | Tip | Steroids, MMF | SR | 24 | 1.7 | 37 | 1710 |
22 | 69/Female | WNH | Tip | Steroids, tacrolimus | SR | 94 | 0.6 | 93 | 4330 |
23 | 56/Female | WNH | Cellular | Steroids | SR | 2 | 1.1 | 56 | 6560 |
24 | 39/Male | WH | Tip | Steroids, cyclosporine | SD | 29 | 1.0 | 94 | 2000 |
eGFR, estimated GFR; WNH, white non-Hispanic; NOS, not otherwise specified; MMF, mycophenolate mofetil; SR, steroid resistant; BNH, black Non-Hispanic; SD, steroid dependent; WH, white Hispanic; BH, black Hispanic; NA, not applicable.
↵a Patients 1 and 12 also underwent plasma exchange therapy.
↵b Patient 1 had undergone four prior renal transplants for recurrent FSGS and was diagnosed with another recurrence 2 months before starting ACTH.